# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Citigroup analyst Paul Lejuez maintains PVH (NYSE:PVH) with a Neutral and lowers the price target from $123 to $72.
Telsey Advisory Group analyst Dana Telsey maintains PVH (NYSE:PVH) with a Outperform and lowers the price target from $130 t...
UBS analyst Jay Sole maintains PVH (NYSE:PVH) with a Buy and lowers the price target from $172 to $160.
Illumina slashes costs by $100 million after China bans its sequencers. The company lowers its 2025 EPS outlook and aims for hi...
China banned imports of Illumina's gene sequencers as new U.S. tariffs took effect, cutting its market access while Chinese...
Goldman Sachs analyst Brooke Roach maintains PVH (NYSE:PVH) with a Buy and lowers the price target from $128 to $109.